- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04341623
Xerosis en gebruik van actuele vochtinbrengende crème
Epidermale permeabiliteit Barrièrefunctie en stratum corneum Hydratatie van xerose na aanbrengen van een plaatselijke vochtinbrengende crème
The primary hypothesis is that routine measurement of trans epidermal water loss (TEWL) rates and stratum corneum (SC) hydration levels will promote patient adherence to maintenance moisturizer therapy and prevent disease relapse. The project will consist of a trial in which thirty subjects with xerosis receive moisturizer therapy and are randomized to receive either no intervention, a weekly electronic survey to assess patient's response to daily moisturizer, or daily monitoring of the effectiveness of a moisturizer with a portable hydration measurement device. The study team will measure adherence to daily moisturizer use objectively in all three groups with electronic monitors attached to the containers of the moisturizer. The adherence measure will allow the study determine how well moisturizers work for xerosis when that are well used. The study team anticipate that in the no intervention group, adherence will be abysmal and that in the group reporting their response to treatment weekly, adherence will be much better. This will give the study team negative and positive controls for assessing the effect of home barrier monitoring on treatment adherence.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Adult subjects will be offered an opportunity to participate in the study. Subjects will have a diagnosis of xerosis in the context (current or historic) of atopic dermatitis. A total of 30 subjects will be enrolled. After consent and basic demographics, a study team member will use the GPSkin Barrier® device to measure the baseline moisture level of the inner wrist, inner elbow, and dorsal hand of all subjects. Subjects will also fill out questionnaires pertaining to quality of life, measures of predictors of adherence, and severity of xerosis.
Subjects will be randomized into one of three arms: the control group (n= 10), the electronic interaction group to assess patient's response to daily moisturizer (n=10), or the GPSkin group (n=10). All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis. The digital interaction group will receive a survey by email each week asking about their Cetaphil use. The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily. Subjects will be instructed to use the Cetaphil once daily. Subjects will return at 3 months. At this visit, the data from the electronic adherence monitoring will be downloaded, the Cetaphil will be weighed, the patient will fill out the same questionnaires (quality of life, measures of predictors of adherence, and severity of xerosis), and the stratum corneum hydration level will be measured. The intervention subjects will be evaluated on their use of the GPSkin Barrier® to measure their stratum corneum hydration
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
North Carolina
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Wake Forest University Health Sciences Department of Dermatology
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Subject is 18 years of age or older.
- Subject has a working knowledge of English.
- Subject with a diagnosis of xerosis in the context (current or historic) of atopic dermatitis
Exclusion Criteria:
- Subjects under 18 years of age.
- Subject does not have a working knowledge of English.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Control Group
All patients will receive Cetaphil Pro Eczema moisturizer equipped with an electronic monitor to measure adherence to daily treatment of xerosis |
All 30 patients to receive |
|
Ander: Digital Interaction Group
The digital interaction group will receive a survey by email each week asking about their Cetaphil use in addition to the electronic monitor measuring the adherence. |
All 30 patients to receive 10 patients to electronic surveys about moisturizer use |
|
Ander: GPSkin group
The patients in the GPSkin group will receive the GPSkin Barrier® to measure the moisture level of their inner wrist, inner elbow, and dorsal hand daily. |
All 30 patients to receive Measuring moisture in the skin |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Xerosis Severity
Tijdsspanne: At Baseline
|
Dry Skin/Ichthyosis Area and Severity Index (DASI) |
At Baseline
|
|
Xerosis Severity
Tijdsspanne: Change from Baseline to 3 months
|
Dry Skin/Ichthyosis Area and Severity Index (DASI) |
Change from Baseline to 3 months
|
|
Adherence - Moisturizer
Tijdsspanne: 3 months
|
MEMs data of daily use of moisturizer |
3 months
|
|
Adherence - Moisturizer
Tijdsspanne: Baseline
|
Weight of moisturizer |
Baseline
|
|
Adherence - Moisturizer
Tijdsspanne: Change from baseline to 3 months
|
Weight of moisturizer |
Change from baseline to 3 months
|
|
Transepidermal water loss (TEWL) rates
Tijdsspanne: Baseline
|
Use of the GPSkin Barrier device a portable hydration measurement device that measures TEWL rates |
Baseline
|
|
Transepidermal water loss (TEWL) rates
Tijdsspanne: Change from baseline to 3 month
|
Use of the GPSkin Barrier device a portable hydration measurement device that measures TEWL rates |
Change from baseline to 3 month
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Steven R Feldman, MD, PhD, Wake Forest University Health Sciences
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- IRB00062695
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Team will determine what will be shared at later time
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .